Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | ACLY | P53396 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29958566 | 1.00 | MAPT (0.43) | MAPTAKR1C3ALDH1A1MEN1KMT2A | |
| SCHEMBL23243620 | 0.87 | MAPT (0.43) | MAPTAKR1C3ALDH1A1MEN1KMT2A | |
| SCHEMBL29632664 | 0.87 | MAPT (0.43) | MAPTAKR1C3ALDH1A1MEN1KMT2A | |
| SCHEMBL31053255 | 0.84 | GAA (0.49) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL7886929 | 0.84 | GAA (0.49) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL5954084 | 0.83 | HPGD (0.42) | ALDH1A1MEN1KMT2AHSP90AB1KDM4E | |
| SCHEMBL7133160 | 0.83 | MAPT (0.49) | MAPTAKR1C3ALDH1A1MEN1KMT2A | |
| SCHEMBL19974304 | 0.83 | MTNR1A (0.50) | ALDH1A1MEN1KMT2AKDM4EGAA | |
| SCHEMBL31092358 | 0.83 | MTNR1A (0.50) | ALDH1A1MEN1KMT2AKDM4EGAA | |
| SCHEMBL13136740 | 0.82 | MAPT (0.42) | MAPTAKR1C3ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-21 | — | — | US | disclosed |
| EP-4401728-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | Boundless Bio, Inc. (US) | 2024-07-24 | — | — | EP | disclosed |
| EP-4308228-A1 | PLASMA KALLIKREIN INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2024-01-24 | — | — | EP | disclosed |
| WO-2023043923-A1 | CYCLIC SULFONAMIDE RIBONUCLEOTIDE REDUCTASE (RNR) INHIBITORS AND USES THEREOF | BOUNDLESS BIO, INC. (US) | 2023-03-23 | — | — | WO | disclosed |
| WO-2022197756-A1 | PLASMA KALLIKREIN INHIBITORS | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| EP-1928829-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | Schering Aktiengesellschaft (DE) | 2008-06-11 | — | — | EP | disclosed |
| EP-1383501-B1 | ACYLATED PIPERIDINE DERIVATIVES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2007-04-04 | — | — | EP | disclosed |
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-07-27 | — | — | US | disclosed |
| WO-2006066948-A1 | PIPERIDINE DERIVATIVES AS ANTAGONISTS OF THE CC CHEMOKINE RECEPTOR CCR1 AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2006-06-29 | — | — | WO | disclosed |
| CN-1633297-A | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO INC (US) | 2005-06-29 | — | — | CN | disclosed |
| CN-1046711-C | Unsaturated hydroxyalkyl quinoline carboxylic acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1999-11-24 | — | — | CN | disclosed |
| US-5856322-A | ANTIALLERGENS, ANTIINFLAMMATORY AGENTS, CARDIOVASCULAR DISORDERS | MERCK FROSST CANADA, INC. (CA) | 1999-01-05 | — | — | US | disclosed |
| EP-0480717-B1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1998-04-15 | — | — | EP | disclosed |
| US-5565473-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS; MONTELUKAST AND ITS SODIUM SALT | MERCK FROSST CANADA, INC. (CA) | 1996-10-15 | — | — | US | disclosed |
| US-5428033-A | Useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotecyive agents | MERCK FROSST CANADA, INC. (CA) | 1995-06-27 | — | — | US | disclosed |
| US-5270324-A | Fluorinated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA, INC. (CA) | 1993-12-14 | — | — | US | disclosed |
| CN-1061408-A | Saturated hydroxyalkyl quinolinic acids as leukotriene antagonists | MERCK FROSST CANADA INC (US) | 1992-05-27 | — | — | CN | disclosed |
| CN-1061407-A | Unsaturated hydroxyalkyl quinoline carboxylic acids as leukotriene antagonists | MERCK FROSST CANADA INC (CA) | 1992-05-27 | — | — | CN | disclosed |
| EP-0480716-A1 | Saturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
| EP-0480717-A1 | Unsaturated hydroxyalkylquinoline acids as leukotriene antagonists | MERCK FROSST CANADA INC. (CA) | 1992-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240382482-A1 | PLASMA KALLIKREIN INHIBITORS | KLKB1, KLK5, KLK1 | MAPT 3323/4885AKR1C3 152/4885ALDH1A1 3175/4885 |
| US-20060167044-A1 | Piperidine derivatives and their use as anti-inflammatory agents | CCR1, CCR2, CCR3 | MAPT 3394/4885AKR1C3 1062/4885ALDH1A1 296/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.